Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (732)	2/17/1998 11:26:00 PM
From: Czechsinthemail	Read Replies (2) \| Respond to of 887

John, With the changing of the guard at DEPO, I've had a lingering concern that the company may have adopted too much of a "don't worry" attitude that minimized the seriousness of side effects and was too casual about their clinical protocols and statistical analyses. If so, these problems may still be present in the Phase IV trial. For example, one question that came up for me was whether use of the steroids to combat arachnoiditis might produce additional negative side effects. Although DEPO management tried to minimize it, the ODAC panel apparently thought the arachnoiditis was a serious concern. It leaves me wondering if their confidence in the steroid solution might also be overly optimistic. I would also like to get more information from anyone who knows more about this. Baird